Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ELEV Elevation Oncology Inc

0.105 (2.89%)
Last Updated: 12:26:33
Delayed by 15 minutes


Draw Mode:

Volume 101,592
Bid Price 3.73
Ask Price 3.75
News -
Day High 3.76


52 Week Range


Day Low 3.63
Company Name Stock Ticker Symbol Market Type
Elevation Oncology Inc ELEV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.105 2.89% 3.735 12:26:33
Open Price Low Price High Price Close Price Prev Close
3.63 3.63 3.76 3.63
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
928 101,592 $ 3.72 $ 378,158 - 0.363 - 5.89
Last Trade Time Type Quantity Stock Price Currency
12:29:03 1 $ 3.75 USD

Elevation Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
181.96M 48.65M - 0 -45.7M -0.94 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Elevation Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ELEV Message Board. Create One! See More Posts on ELEV Message Board See More Message Board Posts

Historical ELEV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.323.943.283.61266,1860.41512.50%
1 Month3.804.493.18013.74752,108-0.065-1.71%
3 Months2.615.82992.534.35985,1061.1343.10%
6 Months0.51655.82990.44012.681,817,8123.22623.14%
1 Year3.645.890.3632.981,400,0030.0952.61%
3 Years14.0016.220.3633.07637,860-10.27-73.32%
5 Years14.0016.220.3633.07637,860-10.27-73.32%

Elevation Oncology Description

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Your Recent History

Delayed Upgrade Clock